These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 11961541)

  • 21. Chelated iron as an anti-Pseudomonas aeruginosa biofilm therapeutic strategy.
    Reid DW; O'May C; Roddam LF; Lamont IL
    J Appl Microbiol; 2009 Mar; 106(3):1058. PubMed ID: 19302101
    [No Abstract]   [Full Text] [Related]  

  • 22. The impact of a cation channel blocker (furosemide) on Pseudomonas aeruginosa PAO1 biofilm architecture.
    Cross JL; Ramadan HH; Thomas JG
    Otolaryngol Head Neck Surg; 2007 Jul; 137(1):21-6. PubMed ID: 17599559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New antimicrobials in the management of cystic fibrosis.
    Høiby N
    J Antimicrob Chemother; 2002 Feb; 49(2):235-8. PubMed ID: 11815562
    [No Abstract]   [Full Text] [Related]  

  • 24. Influence of gentamicin and tobramycin on binary biofilm formation by co-cultures of Burkholderia cepacia and Pseudomonas aeruginosa.
    Al-Bakri AG; Gilbert P; Allison DG
    J Basic Microbiol; 2005; 45(5):392-6. PubMed ID: 16187262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial resistance of Pseudomonas aeruginosa biofilms.
    Drenkard E
    Microbes Infect; 2003 Nov; 5(13):1213-9. PubMed ID: 14623017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of shear stress on growth, adhesion and biofilm formation of Pseudomonas aeruginosa with antibiotic-induced morphological changes.
    Fonseca AP; Sousa JC
    Int J Antimicrob Agents; 2007 Sep; 30(3):236-41. PubMed ID: 17574822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidemiological investigation and glycotyping of clinical Pseudomonas aeruginosa isolates from patients with cystic fibrosis by mass spectrometry: association with multiple drug resistance.
    Altman E; Wang Z; Aaron SD; Liu X; Vandemheen KL; Ferris W; Giesbrecht T; Li J
    J Microbiol Methods; 2009 Feb; 76(2):204-8. PubMed ID: 19000720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of pyocin S2 against Pseudomonas aeruginosa biofilms.
    Smith K; Martin L; Rinaldi A; Rajendran R; Ramage G; Walker D
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1599-601. PubMed ID: 22183174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bacterial biofilms: a common cause of persistent infections.
    Costerton JW; Stewart PS; Greenberg EP
    Science; 1999 May; 284(5418):1318-22. PubMed ID: 10334980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pseudomonas aeruginosa and cystic fibrosis--a nasty bug gets nastier.
    Aaron SD
    Respiration; 2006; 73(1):16-7. PubMed ID: 16498269
    [No Abstract]   [Full Text] [Related]  

  • 31. A cystic fibrosis epidemic strain of Pseudomonas aeruginosa displays enhanced virulence and antimicrobial resistance.
    Salunkhe P; Smart CH; Morgan JA; Panagea S; Walshaw MJ; Hart CA; Geffers R; Tümmler B; Winstanley C
    J Bacteriol; 2005 Jul; 187(14):4908-20. PubMed ID: 15995206
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Azithromycin retards Pseudomonas aeruginosa biofilm formation.
    Gillis RJ; Iglewski BH
    J Clin Microbiol; 2004 Dec; 42(12):5842-5. PubMed ID: 15583321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pseudomonas aeruginosa biofilms in a bronchoalveolar lavage.
    Pusztaszeri M; Aubert JD; Braunschweig R; Mihaescu A
    Diagn Cytopathol; 2009 Nov; 37(11):825. PubMed ID: 19191299
    [No Abstract]   [Full Text] [Related]  

  • 34. Otopathogenic Pseudomonas aeruginosa strains as competent biofilm formers.
    Wang EW; Jung JY; Pashia ME; Nason R; Scholnick S; Chole RA
    Arch Otolaryngol Head Neck Surg; 2005 Nov; 131(11):983-9. PubMed ID: 16301370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Specific maltose derivatives modulate the swarming motility of nonswarming mutant and inhibit bacterial adhesion and biofilm formation by Pseudomonas aeruginosa.
    Shetye GS; Singh N; Jia C; Nguyen CD; Wang G; Luk YY
    Chembiochem; 2014 Jul; 15(10):1514-23. PubMed ID: 24944053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pseudomonas aeruginosa attachment and biofilm development in dynamic environments.
    Ramsey MM; Whiteley M
    Mol Microbiol; 2004 Aug; 53(4):1075-87. PubMed ID: 15306012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterisation of potential virulence markers in Pseudomonas aeruginosa isolated from drinking water.
    Silva ME; Filho IC; Endo EH; Nakamura CV; Ueda-Nakamura T; Filho BP
    Antonie Van Leeuwenhoek; 2008 May; 93(4):323-34. PubMed ID: 18038252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clues to mechanism of Pseudomonas resistance in cystic fibrosis.
    Lawrence D
    Lancet; 2002 Apr; 359(9315):1410. PubMed ID: 11978345
    [No Abstract]   [Full Text] [Related]  

  • 39. Mucin-Pseudomonas aeruginosa interactions promote biofilm formation and antibiotic resistance.
    Landry RM; An D; Hupp JT; Singh PK; Parsek MR
    Mol Microbiol; 2006 Jan; 59(1):142-51. PubMed ID: 16359324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chelated iron sources are inhibitors of Pseudomonas aeruginosa biofilms and distribute efficiently in an in vitro model of drug delivery to the human lung.
    Musk DJ; Hergenrother PJ
    J Appl Microbiol; 2008 Aug; 105(2):380-8. PubMed ID: 18284482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.